Faster European drug reviews
Executive Summary
U.K.'s National Institute for Clinical Excellence announces plans to expedite reviews. NHS division is "in discussion with the Department of Health over proposals for a revised process allowing more rapid appraisal of important new drugs." The proposals were evaluated by NICE's board at a meeting Sept. 21. The European Medicines Agency has also proposed its new framework for Scientific Advice & Protocol Assessment, which "provides for earlier and greater involvement of internal assessors and external experts." Comments are due by Nov. 22. EMEA projects the new review procedure could reduce response time from 100 days to 70 days (1"The Pink Sheet" July 11, 2005, p. 26)...
You may also be interested in...
EMEA Working To Substantially Shorten Scientific Advice Response Time
The European Medicines Agency is developing a new scientific advice procedure aimed at shortening the timeframe for providing drug development feedback to manufacturers
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.